{"title":"Biden backs plan to accelerate vaccine production by waiving patents","link":"https://arstechnica.com/?p=1762850","date":1620252643000,"content":"<div>\n<figure><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2021/05/GettyImages-675026489-800x533.jpg\" /><p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2021/05/GettyImages-675026489.jpg\">Enlarge</a> <span>/</span> Pharmaceutical bottles on a conveyor belt in South Africa. (credit: <a href=\"https://www.gettyimages.com/search/photographer?assettype=image&amp;family=creative&amp;license=rf&amp;photographer=Westend61&amp;sort=best#license\">Westend61 / Getty Images</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>The Biden administration has thrown its weight behind an international effort to loosen patent and other legal protections for COVID vaccines.</p>\n<p>\"The Administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines,\" wrote US Trade Representative Katherine Tai in a Wednesday statement.</p>\n<p>If successful, that effort might open up the vaccine market to independent drugmakers, speeding production and distribution and ending the pandemic more quickly. Or it might not.</p></div><p><a href=\"https://arstechnica.com/?p=1762850#p3\">Read 11 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1762850&amp;comments=1\">Comments</a></p>","author":"Timothy B. Lee","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"f220e318e303b789e8ee3d82cf0ccdd4ae084ffdfaf68a1bdf64eca0d12ff1b4","category":"Tech"}